CJC-1295 with DAC

What is CJC-1295 with DAC?

CJC-1295 with DAC is a synthetic analogue of growth hormone-releasing hormone (GHRH) built on the 29-amino-acid GRF (1-29) sequence with four amino acid substitutions (D-Ala2, Gln8, Ala15 and Leu27) and a C-terminal lysine carrying a maleimidopropionic acid linker known as the Drug Affinity Complex (DAC). The DAC group reacts covalently with cysteine-34 of serum albumin, which protects the peptide from clearance.

This albumin binding is what distinguishes CJC-1295 with DAC from sermorelin and from CJC-1295 No DAC (modified GRF 1-29). Published research on the compound reports a half-life of around six to eight days with sustained elevation of GH and IGF-1 in the models studied, compared with minutes for the unmodified peptide.

GenoPept supplies CJC-1295 with DAC in the UK as a lyophilised research peptide in 2mg, 5mg and 10mg vials. Each batch is verified by independent HPLC and LC-MS testing and is intended strictly for laboratory research.

CJC-1295 with DAC research applications

Long-acting GHRH receptor activation

CJC-1295 with DAC is used in animal models to study the physiological consequences of sustained, rather than pulsatile, GHRH receptor stimulation on GH and IGF-1 output.

Albumin-binding drug delivery

The DAC technology is a model system for research into bioconjugation, covalent albumin binding and half-life extension strategies for peptides.

GH/IGF-1 axis feedback

Researchers use the compound to investigate how somatostatin and IGF-1 feedback shape the GH response when GHRH receptor tone is continuously elevated.

Comparative pharmacokinetics

Side-by-side studies with sermorelin, modified GRF (1-29) and tesamorelin use CJC-1295 with DAC as the long-duration comparator.

Combination secretagogue research

Preclinical studies pair CJC-1295 with DAC with ghrelin receptor agonists such as ipamorelin to examine synergy between the two receptor pathways.

Mechanism of action (preclinical)

CJC-1295 with DAC binds and activates the GHRH receptor on pituitary somatotrophs, a Gs-coupled receptor that raises intracellular cAMP and drives GH synthesis and release. The four amino acid substitutions protect the peptide from dipeptidyl peptidase-4 and other proteases that rapidly degrade native GHRH.

The Drug Affinity Complex extends this action by forming a covalent bond with albumin in circulation, so the peptide is retained and released over days. In preclinical models this produces a prolonged rise in mean GH and IGF-1 levels while GH pulsatility is largely preserved, because the pituitary remains responsive to somatostatin feedback.

CJC-1295 with DAC product specifications

Available sizes

• 2mg vial
• 5mg vial
• 10mg vial

Laboratories running larger studies can order bulk boxes of 10 vials, which save 20-50% against single-vial pricing; see the bulk and wholesale page. Orders over £200 ship free by tracked Royal Mail Special Delivery within the UK.

Reconstitution, handling and storage (laboratory)

CJC-1295 with DAC is supplied as a lyophilised powder that is stable for long-term storage at -20 °C. Unopened vials may be kept at 2-8 °C for short periods, protected from light. Allow a vial to reach room temperature before opening to avoid condensation on the powder.

For reconstitution, add bacteriostatic water or a sterile diluent slowly down the inside wall of the vial, then swirl gently until the powder dissolves. Never shake a peptide vial, because mechanical stress can damage the molecule and reduce measured purity.

After reconstitution, keep the solution at 2-8 °C and use it within the period stated in your laboratory protocol. Full guidance is available in our articles on how to reconstitute research peptides and how to store research peptides.

Quality assurance and Certificate of Analysis

Every batch of CJC-1295 with DAC sold by GenoPept is tested by an independent ISO/IEC 17025 laboratory (Puralytix). HPLC confirms purity of 99% or higher and LC-MS confirms molecular identity, so the compound in the vial matches the label.

Each product page carries a “View Certificate of Analysis” button, and the complete library is published at genopept.co.uk/coa-certificates. Vials are batch-identified with lot number and expiry date, and our guide to what a Certificate of Analysis shows explains how to read the report.

Related research compounds

• CJC-1295 No DAC (Modified GRF 1-29): the same substituted sequence without the albumin-binding linker, for short-acting comparisons.
• CJC-1295 + Ipamorelin Blend: a pre-combined GHRH analogue and ghrelin receptor agonist for synergy studies.
• Sermorelin (GRF 1-29): the unmodified GHRH fragment that CJC-1295 was designed to improve on.
• Tesamorelin: a full-length stabilised GHRH analogue with an extensive published literature.

CJC-1295 with DAC frequently asked questions

What is CJC-1295 with DAC used for in research?

CJC-1295 with DAC is used in laboratory research to study sustained GHRH receptor activation and its effects on the GH/IGF-1 axis in animal models. It is also a model compound for research into albumin-binding bioconjugation and half-life extension, and a long-duration comparator in pharmacokinetic studies alongside sermorelin, modified GRF (1-29) and tesamorelin. Supplied strictly for in-vitro research.

How is CJC-1295 with DAC supplied and what is its purity?

GenoPept CJC-1295 with DAC is supplied as a lyophilised powder in sealed, sterile glass vials of 2mg, 5mg or 10mg. Every batch is tested by an independent ISO/IEC 17025 laboratory, with HPLC confirming purity of 99% or higher and LC-MS confirming molecular identity. The batch Certificate of Analysis is available from the product page and our COA library.

How should CJC-1295 with DAC be stored?

Store unopened lyophilised CJC-1295 with DAC at -20 °C for long-term stability, or at 2-8 °C for short periods, protected from light. After reconstitution with bacteriostatic water, keep the solution refrigerated at 2-8 °C and use it within the period stated in your laboratory protocol. Add diluent gently down the vial wall and swirl rather than shake.

Is CJC-1295 with DAC for human use?

No. CJC-1295 with DAC from GenoPept is supplied for in-vitro laboratory research only. It is not a medicine, is not for human or veterinary use, and is not intended for diagnostic or therapeutic purposes. GenoPept provides no dosing, cycle or administration information, and purchasers must confirm they are buying for legitimate research use in the UK.

What is the difference between CJC-1295 with DAC and CJC-1295 No DAC?

Both share the same tetrasubstituted GRF (1-29) sequence and act at the GHRH receptor. CJC-1295 with DAC adds a lysine-linked maleimidopropionic acid group that covalently binds serum albumin, extending its half-life to several days in published models. CJC-1295 No DAC, also called modified GRF (1-29), lacks this linker and acts for around 30 minutes, producing a short GH pulse.

Research use only. This product is supplied for in-vitro laboratory research only. It is not for human or veterinary use, not a medicine, and not for diagnostic or therapeutic use. See our research use only policy and UK legal guide.